WO2005017112A3 - Methods of inhibiting cancer growth by binding to nuclear receptors - Google Patents

Methods of inhibiting cancer growth by binding to nuclear receptors Download PDF

Info

Publication number
WO2005017112A3
WO2005017112A3 PCT/US2004/023821 US2004023821W WO2005017112A3 WO 2005017112 A3 WO2005017112 A3 WO 2005017112A3 US 2004023821 W US2004023821 W US 2004023821W WO 2005017112 A3 WO2005017112 A3 WO 2005017112A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding
inhibiting cancer
methods
nuclear receptors
cancer growth
Prior art date
Application number
PCT/US2004/023821
Other languages
French (fr)
Other versions
WO2005017112A2 (en
Inventor
Henry Li
Ning Ke
Mirta Grifman
Gisela Claassen
Xiuyuan Hu
Kristin Defife
Cellia Habita
Wufang Fan
Kristina Rhoades
Philip Tan
Flossie Wong-Staal
Original Assignee
Immusol Inc
Henry Li
Ning Ke
Mirta Grifman
Gisela Claassen
Xiuyuan Hu
Kristin Defife
Cellia Habita
Wufang Fan
Kristina Rhoades
Philip Tan
Flossie Wong-Staal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol Inc, Henry Li, Ning Ke, Mirta Grifman, Gisela Claassen, Xiuyuan Hu, Kristin Defife, Cellia Habita, Wufang Fan, Kristina Rhoades, Philip Tan, Flossie Wong-Staal filed Critical Immusol Inc
Priority to EP04779056A priority Critical patent/EP1651752A2/en
Publication of WO2005017112A2 publication Critical patent/WO2005017112A2/en
Publication of WO2005017112A3 publication Critical patent/WO2005017112A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides methods for identifying agents useful for inhibiting cancer cells by binding to various nuclear receptor proteins, or to the genes or RNA encoding such proteins.
PCT/US2004/023821 2003-08-05 2004-07-23 Methods of inhibiting cancer growth by binding to nuclear receptors WO2005017112A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04779056A EP1651752A2 (en) 2003-08-05 2004-07-23 Methods of inhibiting cancer growth by binding to nuclear receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49261803P 2003-08-05 2003-08-05
US60/492,618 2003-08-05

Publications (2)

Publication Number Publication Date
WO2005017112A2 WO2005017112A2 (en) 2005-02-24
WO2005017112A3 true WO2005017112A3 (en) 2009-05-28

Family

ID=34193138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/023821 WO2005017112A2 (en) 2003-08-05 2004-07-23 Methods of inhibiting cancer growth by binding to nuclear receptors

Country Status (2)

Country Link
EP (1) EP1651752A2 (en)
WO (1) WO2005017112A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2323685A2 (en) * 2008-07-11 2011-05-25 Medizinische Universität Innsbruck Agonists of nr2f6 for immunosuppression
WO2010004051A1 (en) * 2008-07-11 2010-01-14 Medizinische Universität Innsbruck Antagonists of nr2f6 for augmenting the immune response
CA2733775A1 (en) * 2008-08-13 2010-02-18 Keio University Agent for promoting neuronal differentiation and method therefor
US20220228155A1 (en) * 2019-05-22 2022-07-21 KSQ Therapeutics, Inc. Nr4a super-repressors and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102572A1 (en) * 1998-03-02 2002-08-01 Isis Pharmaceuticals, Inc. Mass spectrometric methods for biomolecular screening

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102572A1 (en) * 1998-03-02 2002-08-01 Isis Pharmaceuticals, Inc. Mass spectrometric methods for biomolecular screening

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TAYLOR, M.: "Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination.", DDT., vol. 4, no. 12, 1999, pages 562 - 567, XP002952061 *
UEDA, Y.: "Expression of Nerve Growth Factor-Induced Clone B Subfamily and Pro- opiomelanocortin Gene in Lung Cancer Cell Lines.", AM. J. RESPIR. CELL MOL. BIOL., vol. 20, 1999, pages 1319 - 1325, XP008109890 *

Also Published As

Publication number Publication date
WO2005017112A2 (en) 2005-02-24
EP1651752A2 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
WO2005067500A3 (en) Enhancement of immune responses
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2003062375A3 (en) Stabilizing polypeptides which have been exposed to urea
WO2005023824A3 (en) Methods for inhibiting tumor cell proliferation
NO20042570L (en) Antimicrobial polypeptides from Pseudoplectania nigrella
NO20064866L (en) IRTA-5 antibodies and their use
WO2005062977A3 (en) Prostate cancer specific internalizing human antibodies
WO2006028936A3 (en) Heteromultimeric molecules
RS20100555A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2007051164A8 (en) Toll like receptor 3 modulators, methods and uses
IL191142A0 (en) An isolated nucleic acid which encodes a ligand binding fluorescent indicator, multimeric biosensors and methods of using the same
WO2007059190A3 (en) Compositions of and methods of using stabilized psma dimers
TW200621284A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2009030770A3 (en) Methods and tools for prognosis of cancer in er- patients
MX2008002485A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same.
WO2005000207A3 (en) Pcdgf receptor antibodies and methods of use thereof
WO2006017318A3 (en) Methods for treating cancer using agents that inhibit wnt16 signaling
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
TW200700076A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2005017112A3 (en) Methods of inhibiting cancer growth by binding to nuclear receptors
TW200510460A (en) Antimicrobial polypeptides
WO2006053565A3 (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
TW200502253A (en) Antimicrobial polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2004779056

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004779056

Country of ref document: EP